Skip to main content
Erschienen in: AIDS and Behavior 3/2018

28.03.2017 | Original Paper

An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART)

verfasst von: John A. Sauceda, Torsten B. Neilands, Mallory O. Johnson, Parya Saberi

Erschienen in: AIDS and Behavior | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Relying on the most frequently reported barriers to adherence and convenient definitions of non-adherence may lead to less valid results. We used a dominance analysis (a regression-based approach) to identify the most important barriers to adherence based on effect size using data collected through an online survey. The survey included the Adherence Barrier Questionnaire, self-reported non-adherence defined as a 4-day treatment interruption, and HIV clinical outcomes. The sample (N = 1217) was largely male, gay identified, and White. Nearly 1 in 3 participants reported “simply forgot” as a barrier; however, in a dominance analysis, it yielded a small effect size it its association with a 4-day treatment interruption. Further, dominance analyses stratified by race/ethnicity and age suggested that not all barriers impact all groups equally. The most frequently reported barriers to adherence were not the most important, and interventions should focus on barriers more strongly linked to clinical outcomes.
Literatur
1.
Zurück zum Zitat Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in Adults. 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;2016(316):191–210.CrossRef Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in Adults. 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;2016(316):191–210.CrossRef
2.
Zurück zum Zitat Tseng A, Seet J, Phillips EJ. The evaluation of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2014;79:182–94.CrossRef Tseng A, Seet J, Phillips EJ. The evaluation of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2014;79:182–94.CrossRef
3.
Zurück zum Zitat Parienti JJ, Paterson DL. Number of missed doses: why 1 × 7 does not make 7 × 1? AIDS. 2012;26:1437–40.CrossRefPubMed Parienti JJ, Paterson DL. Number of missed doses: why 1 × 7 does not make 7 × 1? AIDS. 2012;26:1437–40.CrossRefPubMed
4.
Zurück zum Zitat The Breather (Penta 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomized, open-label, non-inferiority, phase 2/3 trial. Lancet HIV. 2016;3:e421–30.CrossRef The Breather (Penta 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomized, open-label, non-inferiority, phase 2/3 trial. Lancet HIV. 2016;3:e421–30.CrossRef
5.
Zurück zum Zitat Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26:1415–23.CrossRefPubMedPubMedCentral Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26:1415–23.CrossRefPubMedPubMedCentral
6.
7.
Zurück zum Zitat Mills EJ, Nachega JB, Bangsberg DR. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:2039–64. Mills EJ, Nachega JB, Bangsberg DR. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:2039–64.
8.
Zurück zum Zitat Barfod T, Sorensen H, Nielsen H, Rodkjaer L, Obel N. “Simply forgot” is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence. HIV Med. 2006;7:285–90.CrossRefPubMed Barfod T, Sorensen H, Nielsen H, Rodkjaer L, Obel N. “Simply forgot” is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence. HIV Med. 2006;7:285–90.CrossRefPubMed
9.
Zurück zum Zitat Saberi P, Neilands TB, Vittinghoff E. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS Clinical Trials Group study participants. AIDS Patient Care STDS. 2015;29:111–6.CrossRefPubMedPubMedCentral Saberi P, Neilands TB, Vittinghoff E. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS Clinical Trials Group study participants. AIDS Patient Care STDS. 2015;29:111–6.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.CrossRefPubMedPubMedCentral Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–45.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat O’Connor JL, Gardner EM, Esser SB, et al. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy. HIV Med. 2016;17:124–32.CrossRefPubMed O’Connor JL, Gardner EM, Esser SB, et al. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy. HIV Med. 2016;17:124–32.CrossRefPubMed
12.
Zurück zum Zitat Haberer JE, Nicholas M, Yap Boum, et al. Duration of antiretroviral therapy adherence interruption is associated with risk of virologic rebound as determined by real-time adherence monitoring in Rural Uganda. J Acquir Immune Defic Syndr. 2015;70:386–92.CrossRefPubMedPubMedCentral Haberer JE, Nicholas M, Yap Boum, et al. Duration of antiretroviral therapy adherence interruption is associated with risk of virologic rebound as determined by real-time adherence monitoring in Rural Uganda. J Acquir Immune Defic Syndr. 2015;70:386–92.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Yuan P, Bare MG, Johnson MO, Saberi P. Using online social media for recruitment of Human Immunodeficiency Virus-positive participants: a cross-sectional survey. J Med Internet Res. 2015;16:e117.CrossRef Yuan P, Bare MG, Johnson MO, Saberi P. Using online social media for recruitment of Human Immunodeficiency Virus-positive participants: a cross-sectional survey. J Med Internet Res. 2015;16:e117.CrossRef
14.
Zurück zum Zitat Kalichman SC, Rompa D, Cage M. Reliability and validity of self-reported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STDS AIDS. 2000;11:579–85.CrossRef Kalichman SC, Rompa D, Cage M. Reliability and validity of self-reported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STDS AIDS. 2000;11:579–85.CrossRef
15.
Zurück zum Zitat Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255–66.CrossRefPubMed Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255–66.CrossRefPubMed
16.
Zurück zum Zitat Saberi P, Yuan P, John M, Sheon N, Johnson MO. A pilot study to engage and counsel HIV-positive African American youth via telehealth technology. AIDS Patient Care STDS. 2013;27:529–32.CrossRefPubMedPubMedCentral Saberi P, Yuan P, John M, Sheon N, Johnson MO. A pilot study to engage and counsel HIV-positive African American youth via telehealth technology. AIDS Patient Care STDS. 2013;27:529–32.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Sauceda JA, Johnson MO, Saberi P. Nonadherence as 4-day antiretroviral therapy interruptions: do depression and race/ethnicity matter as much in the modern antiretroviral therapy era? AIDS Behav. 2016;20:2624–8.CrossRefPubMedPubMedCentral Sauceda JA, Johnson MO, Saberi P. Nonadherence as 4-day antiretroviral therapy interruptions: do depression and race/ethnicity matter as much in the modern antiretroviral therapy era? AIDS Behav. 2016;20:2624–8.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12:86–94.CrossRefPubMed Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008;12:86–94.CrossRefPubMed
19.
Zurück zum Zitat Azen R, Budescu DV. The dominance analysis approach for comparing predictors in multiple regression. Psychol Methods. 2003;8:129–48.CrossRefPubMed Azen R, Budescu DV. The dominance analysis approach for comparing predictors in multiple regression. Psychol Methods. 2003;8:129–48.CrossRefPubMed
20.
Zurück zum Zitat Budescu DV. Dominance analysis: a new approach to the problem of relative importance of predictors in multiple regression. Psychol Bull. 1993;114:542–51.CrossRef Budescu DV. Dominance analysis: a new approach to the problem of relative importance of predictors in multiple regression. Psychol Bull. 1993;114:542–51.CrossRef
21.
Zurück zum Zitat Tonidandel S, LeBreton JM. Relative importance analysis: a useful supplement to regression analysis. J Bus Psychol. 2011;26:1–9.CrossRef Tonidandel S, LeBreton JM. Relative importance analysis: a useful supplement to regression analysis. J Bus Psychol. 2011;26:1–9.CrossRef
23.
Zurück zum Zitat Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25:279–90.CrossRefPubMed Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25:279–90.CrossRefPubMed
24.
Zurück zum Zitat Rubinstein ML, Selwyn PA. High prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr. 1998;1:260–5.CrossRef Rubinstein ML, Selwyn PA. High prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr. 1998;1:260–5.CrossRef
25.
Zurück zum Zitat Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among Human Immunodeficiency Virus–infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.CrossRefPubMed Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among Human Immunodeficiency Virus–infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.CrossRefPubMed
26.
Zurück zum Zitat Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58:1297–307.CrossRefPubMedPubMedCentral Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58:1297–307.CrossRefPubMedPubMedCentral
Metadaten
Titel
An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART)
verfasst von
John A. Sauceda
Torsten B. Neilands
Mallory O. Johnson
Parya Saberi
Publikationsdatum
28.03.2017
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 3/2018
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-1759-9

Weitere Artikel der Ausgabe 3/2018

AIDS and Behavior 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.